Introduction
Normal cell survival is governed by signalling pathways modulating cell death and proliferation. Drivers of these pathways include growth factors, neurotrophins, cytokines and haematopoietins.
The epidermal growth factor receptor tyrosine kinase (EGFR-TK) signalling pathway has been identi®ed as a key driver of cell proliferation. 1, 2 The EGFR is part of a subfamily of four closely related receptors, EGFR (or ErbB-1), Her 2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). 3 The EGF receptors exist as monomers, which dimerize following ligand activation (eg EGF, TGFa, amphiregulin or betacellulin). 4 Homodimerization between two EGFR receptors or heterodimerization between EGFR and another member of the erb receptor family can occur. On binding of the ®rst ligand to the EGFR dimer, the TK intracellular domain of the receptor is activated, transphosphorylating both intracellular domains, which in turn initiates a cascade of events leading to a number of processes including cell proliferation, since EGFR signalling induces cyclin D1, a protein required for cell cycle progression from G1. 5 EGFR-mediated signalling also contributes to a number of processes that are crucial to tumour progression, including angiogenesis, metastatic spread and inhibition of apoptosis. 6, 7 EGF can act as an angiogenic factor in vitro, and inhibiting the EGFR has been reported to inhibit vascular endothelial growth factor in vivo. 8, 9 Studies have also shown that EGF and EGF family ligands promote tumour cell motility, adhesion and invasion, associated with a metastatic phenotype. 10, 11 EGFR-mediated drive is increased in a range of human solid tumours, including prostate, non-small cell lung, breast, gastric, colorectal adenomas and head and neck cancer. 12 ± 14 Heightened EGFR activity can occur due to overexpression of the EGFR, increased concentration of ligands, decreased phosphatase activity, decreased receptor turnover or the presence of aberrant receptors or receptor mutation. 15 EGFR-mediated drive has been shown to be associated with advanced disease and a poor prognosis in a wide variety of tumour types. 13 In accordance with this, the expression of the EGFR has been used as a predictive factor for breast cancer risk and for molecular staging in non-small cell lung cancer (NSCLC). 16, 17 Overexpression of EGFR has also been correlated with tumour resistance to cytotoxic agents and radiation. 18, 19 treatment for advanced prostate cancer for many years has been androgen deprivation, ie bilateral orchidectomy, luteinizing hormone-releasing hormone (LHRH) analogues and anti-androgens. Although these treatments result in stabilization or regression of disease in approximately 80% of patients, the survival rates of these patients remain low, 21 because most of these patients will eventually progress to hormone-resistant disease. 22 At present, no effective treatment option exists for patients with advanced hormone-resistant prostate cancer, whose median survival is under one year. 23 Cytotoxic chemotherapy results reported in the 1980s and early 1990s showed response rates of 8.7%. 24 Recent publications of estramustine-or taxane-based regimens have shown preliminary response rates between 24 and 60% in small numbers of patients with measurable disease. Large phase III trials are underway to de®ne the ef®cacy of these regimens and to evaluate the effect of these agents on survival in patients with hormone-refractory prostate cancer. 25, 26 However, despite improved response rates, a survival bene®t has not yet been demonstrated. New cellular targets for the treatment of these patients are still needed.
Various molecules involved in cell proliferation, apoptosis and angiogenesis may offer alternative approaches for treating hormone-resistant prostate cancer. 27 Cellular proliferation is increased in recurrent prostate tumours after radiotherapy or surgery. 28 Many aberrant pathways in tumours could lead to increased cellular proliferation and a wide range of aberrant signal transduction pathways have been implicated in prostate cancer, including EGFR signalling (Figure l) . 27, 29 Cross-talk between the androgen and EGFR signalling pathways may play a signi®cant role in prostate cancer development, as androgen has been shown to up-regulate EGFR expression in PC-3 cells expressing the androgen receptor (AR). 30 In addition, EGF can directly activate the AR in the absence of androgens. 31 Progression of prostate cancer is accompanied by modi®cations of the expression of growth factors and their receptors as well as changes from paracrine to autocrine growth. A large body of evidence suggests that EGF/TGFa contributes to the autonomous growth of prostate cancer cells through the EGFR and that EGF has a pleiotropic effect on human prostate cancer cells, promoting both growth and invasiveness. 12 For example, pre-treatment of PC-3 androgen-independent prostate carcinoma cells with an antibody that blocks EGFR blocked the growth stimulatory effects of TGFa. 32 Moreover, EGFR is overexpressed in prostate cancer and EGFR expression is correlated with high grade and less differentiated prostate tumours. 12, 33 In breast cancer, where hormone resistance is also a major problem, EGFR is overexpressed and the expression of EGFR is inversely correlated with oestrogen Figure 1 Defective signalling pathways in prostate cancer (adapted from Green & Furr 1999) . 27 Cellular proliferation in tumours is induced by deregulated signalling pathways that increase the activity of cyclin-dependent kinases (CDK). Some of the pathways increase the level of cyclin D, an activator of CDK4 and CDK6, whereas others modulate the activity of CDK2 by decreasing the levels of CDK inhibitors such as p27 Kip1 . The net effect is accelerated entry into the cell cycle and a lower dependency on growth factors. Smad proteins are a recently identi®ed family of signal transducers which act as transcriptional regulators through binding to DNA and interacting with a variety of transcription factors. RI/RII, receptor I and II; PDGF, plateletderived growth factor. receptor expression. 34 Interestingly, Hutcheson and colleagues have recently demonstrated that a switch from endocrine to EGFR signalling may be an important mechanism of cell survival in some endocrine-resistant breast cancers. 35 MCF-7 breast cancer cells resistant to tamoxifen and ZM182,780 (oestrogen receptor downregulator) were shown to have a 10-fold increase in EGFR levels compared with parental MCF-7 oestrogen sensitive cells. Several ligands of the EGFR (TGFa, epiregulin, betacellulin) were also constitutively expressed by the resistant cells. 35 If a similar survival mechanism occurs in hormonerefractory prostate cancer, bene®t may be derived from treatment with an agent that inhibits the EGFR-TK pathway. 27 This article reviews preliminary evidence to support the investigation of ZDl839 (`Iressa'), an orally active, selective EGFR-tyrosine kinase inhibitor (EGFR-TKI), in patients with prostate cancer.
ZD1839
ZD1839 (4-(3-chloro-4-¯uoroanilino)-7-methoxy-6-(3-morpholinopropoxy) quinazoline) is a novel low molecular weight, synthetic anilinoquinazoline ( Figure 2 ). 36 ZD1839 is an orally active, selective EGFR-TKI which blocks the signal transduction pathways implicated in proliferation and survival of cancer cells, and other host-dependent processes promoting cancer growth.
Preclinical data
In vitro studies. ZD1839 is a highly speci®c inhibitor of EGFR-TK. ZD1839 inhibited autophosphorylation of EGFR-TK isolated from A431 human vulval squamous carcinoma cells, with an IC 50 of 0.023 ± 0.079 mM (K is 0.0021 mM). 37 By contrast, ZD1839 exhibited minimal activity against the tyrosine kinases erbB2, KDR and c-¯t, and the serine/threonine kinases protein kinase C, rat MEK1 and ERK-2. ZD1839 reversibly inhibited in vitro growth of KB oral carcinoma cells, with an IC 50 of 0.08 mM. 37 Cytostatic ZD1839 activity has been demonstrated in a wide range of tumour cell lines including prostate, ovarian, breast, colon, vulval, small cell lung (SCL) and non-small cell lung (NSCL). 37 ± 42 In addition, ZD1839 treatment can also be associated with a doserelated increase in apoptosis in vitro. 38 Furthermore, ZD1839 has been shown to induce G1 arrest in human head and neck squamous cell carcinoma (HNSCC) cell lines by disrupting regulation of cyclin-dependent kinase 2 (CDK2), via a dose-and time-dependent upregulation of p27 Kip1 cyclin-dependent kinase inhibitor. 43 This suggests that p27 Kip1 plays a key role in ZD1839-induced cell cycle perturbation by decreasing CDK2 activity and leading to growth arrest.
As previously described, a recent study by Hutcheson and colleagues has shown that in vitro oestrogen-sensitive breast cancer cells, MCF-7, express only modest levels of EGFR, compared with hormone-resistant variants of these cells which express 10-fold higher levels of EGFR. The oestrogen-sensitive MCF-7 cells were relatively insensitive to ZD1839 in vitro, whereas hormone-resistant variants of these cells were inhibited by ZD1839 in vitro, despite maintaining oestrogen receptor levels. 35 The responses to ZD1839 lasted for more than 150 days, which suggested that EGFR signalling was an important survival mechanism in these cells. Moreover, administration of ZD1839 to these cells during the period during which they would usually develop resistance to tamoxifen resulted in a signi®cant delay in the appearance of hormone-resistant cells. 35 In vivo studies. Daily oral administration of single-agent ZD1839 (12.5 ± 200 mg/kg) to athymic nude mice caused marked reductions in tumour growth in a variety of human tumour xenografts, including prostate, ovarian, breast, colon, vulval, SCL and NSCL. 37 ± 42 Administration of ZD1839 (1.25 ± 5 mg/mouse/day) to nude mice bearing human GEO colon cancer xenografts for 4 weeks produced a dose-dependent inhibition of tumour growth. Once treatment with ZD1839 ceased, tumours resumed a growth rate comparable with that observed in controls. 38 ZD1839 demonstrates similar antitumour activity in xenograft models with differing levels of EGFR expression, although tumours such as A431 with high expression of EGFR responded well and tumours with no detectable expression, such as LX-1, responded less well. 41 A431 xenografts were also used to investigate the effect of ZD1839 on c-fos mRNA, a downstream biomarker for EGFR-TK activation. Following administration of ZDl839 to mice bearing A431 xenografts, there was a time-and dose-dependent decrease in c-fos mRNA. The inhibition of c-fos correlated with tumour drug concentrations and with tumour growth inhibition. 42 Interestingly, ZD1839 has also been shown to inhibit the growth of ductal carcinoma in situ (DCIS) breast xenografts by decreasing proliferation and increasing apoptosis; 39 more than 50% of DCIS of the breast is normally hormone independent. 44 This supports the work of Hutcheson and colleagues who also demonstrated that ZD1839 inhibited the growth of hormoneresistant breast cancer cells in vitro. Studies have also shown that ZD1839 treatment results in reduced tumour mass in nude mice bearing human hormone-independent prostate (TSU-PrI, PC-3, DU145) tumour xenografts. 41, 42 In the DU145 prostate xenograft, up to an 85% inhibition of tumour growth was observed with ZD1839 200 mg/kg. 42 ZD1839 in combination with a range of cytotoxic agents has shown promising activity in several human tumour xenografts, including those derived from prostate 
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cancer. Enhancement of cell growth inhibition, apoptosis and increased antitumour activity were observed when ZD1839 was combined with cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, doxorubicin, etoposide, topotecan and raltitrexed. 38, 41 ZD1839 combination therapy was associated with a signi®cant inhibition of tumour growth ( Figure 3a ) and a signi®cant increase in survival of nude mice with GEO tumour xenografts, especially when ZD1839 was combined with paclitaxel. 38 In nude mice bearing prostate tumour xenografts TSUPrI and PC-3, ZD1839 in combination with cytotoxic agents enhanced antitumour activity and in some cases produced tumour regression (Table 1 and Figure 3b ). 41 
Preliminary clinical results
Encouraging results from the preclinical studies described above and the observation that ZD1839 alone and in combination was generally well tolerated in mice, led to the initiation of a phase I clinical trial programme with ZD1839. Patients with solid malignant tumours of types known to express or overexpress EGFR, including hormone-resistant prostate cancer, were treated with either intermittent ZDl839 (14 days' treatment, then 14 days' observation), 45, 46 or continuous ZD1839 (28 consecutive days' treatment). 47 ZD1839 was administered as a oncedaily, oral dose (50 ± 1000 mg/day). Preliminary results are reported brie¯y here. 
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Nearly all of the patients in the phase I trials were heavily pre-treated, with almost 30% failing more than two prior chemotherapy regimens. A summary of patient numbers by tumour type is given in Table 2 . 45 ± 47 Pharmacokinetic assessments con®rm that ZDl839 is suitable for once-daily dosing; the mean elimination half life was 46 h. 45 Steady-state plasma concentrations were achieved by day 7 of dosing. Exposure to ZDl839 (C max and AUC 0 ± 24 ) increased approximately linearly with dose, although exposure varied within each dose group (3 ± 10 fold at doses of 150 ± 400 mg). 47 This was consistent with results from two placebo-controlled pharmacokinetic studies in healthy volunteers (n 28). 48 Both intermittent and continuous dosing of ZDl839 were well tolerated. The most frequently reported NCI-CTC grade 1 ± 2 adverse events were diarrhoea and an acneiform skin rash. 45, 47 Adverse events were reversible on discontinuation of treatment and the skin rash resolved without scarring. Nausea and vomiting were also reported frequently, although the relationship to ZD1839 is unclear. Grade 3 ± 4 adverse events were rare and usually related to disease progression. 45, 47 Intermittent ZD1839 treatment was also well tolerated in Japanese patients; grade 3 elevation in transaminases was observed in one patient. 46 Four patients were withdrawn from the ZD1839 continuous treatment regimen due to drugrelated toxicity: three patients with grade 3 diarrhoea (two patients at 300 mg dose level and one patient at the 600 mg dose level) and one patient with a grade 3 skin rash (400 mg dose level). 47 Grade 3 diarrhoea was doselimiting at the 700 mg dose level after intermittent dosing and 1000 mg after continuous dosing. 45, 47 Antitumour activity (including disease stabilisation), as assessed by UICC/WHO criteria (intermittent dosing) and WHO RECIST criteria (continuous dosing), has been observed in patients with colorectal, ovarian, NSCL, head and neck, renal and hormone-resistant prostate cancers. 45, 47 In particular, encouraging results have been reported in patients with NSCLC. Of 64 patients with NSCLC, 30% have had either stable or improved disease. 45, 47 This includes four patients who had partial responses and two patients who had minor responses. 45, 47 Of the 19 patients with hormone-resistant prostate cancer in these trials, one patient receiving continuous ZD1839 (225 mg) showed a partial response for 48 weeks. 47 Five additional patients had stable disease for at least 3 months (225 mg, two patients; 600 mg/800 mg/1000 mg, one patient each). 45, 47, 49 Preliminary data from NSCLC patients receiving continuous ZD1839 indicate that improvements in disease status are linked with improvements in FACT-L quality-of life scores and disease-related symptoms. 47 Improvements in disease-related symptoms were also observed in patients with prostate cancer. A 67-y-old patient with metastatic hormone-resistant prostate cancer receiving continuous ZD1839 dosing (225 mg) had a reduction in measurable disease in a nodal metastasis and a 70% reduction in serum prostate-speci®c antigen (PSA) and declining alkaline phosphatase levels, accompanied by pain relief allowing discontinuation of morphine ( Figure  4 ). 50 Symptom improvements were also observed in patients who received ZDl839 on the intermittent dosing schedule. 45 
Discussion
ZD1839 is an orally active, selective EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) which blocks signal transduction pathways implicated in cancer growth. ZD1839 is generally well tolerated in patients, and while diarrhoea and skin reactions were dose limiting at high doses, these toxicities were mainly grade I/II at the doses chosen for phase III evaluation in NSCLC and hormone-resistant prostate cancer (250 and 500 mg/day). The phase I data are promising with patients deriving bene®t from tumour regression and stable disease with symptomatic relief. The preliminary results from phase I trials, indicating that ZD1839 has ef®cacy in patients with advanced cancer, including hormone-resistant prostate cancer, support further work. Moreover, data from preclinical studies support the potential for combining ZD1839 treatment with cytotoxic drugs. ZDl839's good tolerability pro®le also points to its potential use in earlier stages of the disease as well as monotherapy in patients in the very terminal stages of illness. ZD1839 potentially offers a new approach to the treatment of a variety of solid tumours, including hormone-resistant prostate cancer, where new treatments are urgently needed. .
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